The Treatment of Painful Diabetic Neuropathy.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing existing evidence and expert consensus without systematic search methodology
PubMed 34238163 · doi:10.2174/1573399817666210707112413
What was done
This narrative review synthesizes current evidence, clinical guidelines, and emerging therapeutic approaches for managing symptomatic painful diabetic peripheral neuropathy (painful-DPN).
What was found
The abstract reports no primary numerical data or pooled effect sizes. It notes that painful-DPN affects up to one-third of people with diabetes and that phase 3 trials for disease-modifying agents have failed. Recommended first-line and standard symptomatic pharmacotherapies have remained largely unchanged over the past decade: duloxetine (an SNRI) and pregabalin (an α2δ ligand) have the strongest supporting evidence, alongside amitriptyline, gabapentin, and weak opioids with SNRI activity (tramadol, tapentadol). Newer locally approved options include mirogabalin in Japan and the 8% capsaicin patch in the US and Europe. Robust clinical trial evidence remains lacking for combination pharmacotherapies and refractory off-label interventions like botulinum toxin, intravenous lidocaine, and spinal cord stimulation.
Why it matters
It highlights the current standard of care for a highly prevalent diabetic complication, underscoring the persistent lack of disease-modifying therapies and the necessity for biomarker- or phenotype-driven treatment stratification.
Limits
As a narrative review, it lacks a systematic literature search, standardized risk-of-bias evaluation, and quantitative meta-analysis. No numerical outcome measures, responder proportions, or safety data are reported in the abstract.
Cited by
- supports There are no FDA-approved drugs in the United States to treat the underlying nerve degeneration and loss in diabetic neuropathy.